Cue Biopharma, Inc. — Q1 2022 Form 10-Q
Business context and reporting period
Clinical-stage biopharmaceutical company developing Immuno-STAT biologics. This unaudited report covers the three months ended March 31, 2022; comparisons are with Q1 2021. Cue has no commercial product revenue and remains dependent on collaboration revenue and external financing.
Financial performance and liquidity
| Metric | Q1 2022 | Q1 2021 / prior date |
|---|---|---|
| Collaboration revenue | $1.000 million | $1.553 million |
| Research and development expense | $10.082 million | $9.816 million |
| General and administrative expense | $5.156 million | $4.255 million |
| Operating loss | $14.238 million | $12.518 million |
| Net loss | $14.255 million; $0.44 per share | $12.505 million; $0.41 per share |
| Cash used in operating activities | $11.573 million | $11.795 million |
At March 31, cash and cash equivalents were $67.927 million; current assets were $75.947 million and current liabilities $11.411 million. Total assets were $90.704 million and total liabilities $26.031 million, including $9.861 million of long-term debt, net. The company reported no gross margin. It believes cash on hand will fund operations for at least 12 months from the financial statements’ issuance date, but states that additional capital will be needed over time.
Financing activities provided $15.156 million, including $10.000 million drawn under a new SVB term loan and $5.489 million of net ATM proceeds received during the quarter. A further $5.127 million from shares sold by quarter-end was recorded as a receivable and collected in April. The company also sold 1,919,826 shares through its ATM program during the quarter.
Material changes versus the prior comparable period
- Revenue fell $553,000, mainly because the Merck research collaboration term expired on December 31, 2021. Q1 2022 collaboration revenue was from LG Chem.
- Operating expenses rose $1.167 million, led by a $901,000 increase in G&A; R&D increased $266,000. Net loss increased $1.750 million.
- Operating cash use was modestly lower year over year. Financing shifted upward due to the SVB borrowing and ATM stock sales; Q1 2021 investing cash inflow had included redemption of $10 million in short-term investments.
- Common shares outstanding increased to 34,174,800 at March 31 from 32,202,496 at December 31, 2021, primarily reflecting ATM issuance.
Outlook, management commentary, and risks
- Management is prioritizing oncology programs in the CUE-100 series and seeking partners or other funding structures for CUE-200, CUE-300, and CUE-400.
- CUE-101 was in Phase 1b monotherapy and first-line combination trials with pembrolizumab. The company reported completion of monotherapy expansion enrollment at the 4 mg/kg recommended Phase 2 dose and preliminary activity, including one confirmed partial response and six cases of confirmed stable disease among 14 evaluable patients at that dose. These are early clinical findings, not evidence of established efficacy.
- The FDA accepted the CUE-102 IND filed March 31, 2022, for a planned Phase 1 trial. Management cited prior manufacturing delays and supply-chain disruptions; it also warned that COVID-19 or third-party disruptions could affect development.
- The SVB loan bears a floating rate (5.75% at March 31), has interest-only payments through June 2023, and then scheduled principal amortization. Up to another $10 million is conditionally available. Debt is secured by substantially all assets other than intellectual property, which is subject to a negative pledge; covenants require specified cash to be maintained at SVB. Repayment carries a 5% final payment fee and potential prepayment premiums.
- After quarter-end, the company reported approximately $6.0 million of additional net ATM proceeds and relocation to a new Boston facility under a lease extending to April 2026. The new lease was expected to add about $9.1 million of right-of-use asset and lease liability at commencement; the prior 21 Erie Street lease was terminated effective April 30, 2022.
- Key risks include clinical and regulatory uncertainty, recurring losses, future financing needs and possible dilution, dependence on third parties for trials and manufacturing, collaboration restrictions, competition, and the possibility that existing capital may be insufficient if assumptions change. No material legal proceedings or contingent-liability accruals were reported. Management said disclosure controls were effective at quarter-end.
Important facts for investors to verify
- Whether the reported CUE-101 responses and tolerability remain durable as trials expand, and what subsequent clinical data show.
- Whether CUE-102 development proceeds on schedule following IND acceptance and whether manufacturing or supply constraints recur.
- Cash runway assumptions, future operating cash use, ATM issuance and dilution, and the availability and conditions for the additional SVB tranche.
- Loan covenant compliance, floating-rate exposure, repayment terms, and the effects of the new lease and prior lease termination on future cash needs.
- Future collaboration revenue and milestones: no development, regulatory, commercial milestone or royalty revenue had been recognized to date.